ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

MOUNTAIN VIEW, Calif., Sept. 8, 2020 – ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 1:30 p.m. ET. A live audio webcast will be available on the company’s website and a replay will be accessible for two weeks post-presentation. ChemoCentryx focuses on developing targeted therapies for inflammatory and autoimmune diseases and cancer, with its lead drug candidate avacopan undergoing FDA review following a pivotal Phase III trial.

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET.

A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered, targeted therapies. ChemoCentryx’s lead drug candidate, avacopan, completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application (NDA) has been submitted to the FDA. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The Company also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer, including an orally-administered small molecule checkpoint inhibitor of PD-1/PD-L1. For more information, please visit www.chemocentryx.com

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com                                          

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Steven Klass, Burns McClellan
212.213.0006
Sklass@burnsmc.com

FAQ

When will ChemoCentryx CEO Thomas J. Schall present at the H.C. Wainwright conference?

Thomas J. Schall will present on September 15, 2020, at 1:30 p.m. ET.

How can I access the live webcast of the ChemoCentryx presentation?

The live audio webcast can be accessed through the Investors section of ChemoCentryx's website.

What is ChemoCentryx's lead drug candidate?

ChemoCentryx's lead drug candidate is avacopan, which is under FDA review.

What conditions is avacopan being developed to treat?

Avacopan is being developed for ANCA-associated vasculitis, C3 glomerulopathy, and hidradenitis suppurativa.